China Biologic Products Holdings, Inc.
Healthcare · Biological Products, (No Diagnostic Substances) · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | |
|---|---|---|---|---|---|---|
| Revenue | $341.2M | $296.5M | $243.3M | $203.4M | $184.8M | $153.1M |
| Operating income | $143.9M | $132.6M | $111.2M | $86.9M | $74.5M | $32.2M |
| Net income | $104.8M | $89.0M | $70.9M | $54.6M | $45.2M | $18.2M |
| Total assets | $605.0M | $551.5M | $446.8M | $403.8M | $311.0M | $248.9M |
| Total liabilities | $83.8M | $84.5M | $171.6M | $99.8M | $53.6M | $69.9M |
| Equity | $462.2M | $382.3M | $212.1M | $237.7M | $195.5M | $135.5M |
| EPS (diluted) | $3.74 | $3.27 | $2.71 | $1.96 | $1.62 | $0.37 |
| Shares out. | 26.6M | 24.8M | 23.4M | 26.8M | 25.6M | 25.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2016- Operating margin
- 42.2%
- Net margin
- 30.7%
- Return on equity
- 22.7%
- Return on assets
- 17.3%
- Return on capital (ROCE)
- 27.1%
- Liabilities / assets
- 13.9%
- Debt / equity
- 0.18×
- Book value / share
- $17.38
- Revenue growth (YoY)
- 15.1%
- Net income growth (YoY)
- 17.7%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2016- Altman Z″ (distress)
- 13.22safe
- Accruals / assets
- −3.1%clean
- Beneish M-Score
- -2.36normal
- Piotroski F-Score
- 7/9strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 7 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating margin is positive
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 16, 2011
- NT 10-Qmissed a reporting deadline ↗Nov 15, 2007
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Material events
SEC Form 8-K · most recent- Other material eventJul 21, 2017
- Shareholder voteJun 30, 2017
- Results of operations · Regulation FD disclosureMay 3, 2017
- Entered a material agreementApr 28, 2017
- Results of operations · Regulation FD disclosureFeb 23, 2017
- Other material eventJan 6, 2017
- Regulation FD disclosureJan 4, 2017
- Other material eventNov 8, 2016
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- CT ORDERJul 11, 2023
- SC 13D/AMay 12, 2023
- CT ORDERMay 3, 2023
- 15-12BApr 30, 2021
- SC 13D/AApr 22, 2021
- SC 13D/ACHINA BIOLOGIC PRODUCTS HOLDINGS, INC.Apr 22, 2021
- SC 13D/ASCHEDULE 13D/AApr 22, 2021
- SC 13D/ASCHEDULE 13D/AApr 22, 2021
- SC 13D/AApr 22, 2021
- SC 13D/ASC 13DAApr 21, 2021
- S-8 POSApr 21, 2021
- S-8 POSApr 21, 2021
- SC 13E3/AApr 21, 2021
- 6-KFORM 6-KApr 20, 2021
- 25-NSEApr 20, 2021
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.